Release Date: October 20, 2009
Expiration Date: October 20, 2010
Estimated time to complete activity: 1.5 hours

Nicholas S. Hill, MD
Program Chairman
Chief, Pulmonary, Critical Care and Sleep Division Tufts-New England Medical Center
Professor of Medicine
Tufts University School of Medicine
Medical Director of Outpatient Pulmonary Rehabilitation
New England Sinai Hospital
Boston, MA

Mardi Gomberg-Maitland, MD, MSc
Assistant Professor of Medicine, Division of Cardiology
Director, Pulmonary Hypertension Center
University of Chicago Medical Center
Chicago, IL

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension
LA Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, CA

Myung H. Park, MD, FACC
Assistant Professor of Medicine, Division of Cardiology
Director, Pulmonary Vascular Disease Program
University of Maryland School of Medicine
Baltimore, MD

Roham T. Zamanian, MD, FCCP
Assistant Professor of Medicine
Director, Adult Pulmonary Hypertension Clinical Service
Division of Pulmonary & Critical Care Medicine
Vera Moulton Wall Center for Pulmonary Vascular Disease
Stanford University School of Medicine
Stanford, CA
 

Clinicians who diagnose and treat pulmonary arterial hypertension (PAH), including cardiologists, pulmonologists, rheumatologists, and critical care physicians and nurses, confront a range of issues concerning optimal treatment of PAH. As knowledge of the underlying pathogenesis and clinical trial evidence for available and potential therapies continues to evolve, the challenges of treatment selection become more complex. This monograph will review current and emerging concepts in the pathogenesis and treatment of World Health Organization  (WHO) Group 1 PAH as presented by key opinion leaders in the field. Discussion among faculty members is presented after each topic presentation. Topics covered include pathogenic mediators of PAH, the role of treatment, expert opinion and consensus in selection of PAH treatments, recent clinical trial evidence for first-line therapies, appropriate use of monotherapy and combination therapy, rational selection of optimal therapy for the individual patient, and emerging treatments for PAH.
 

Cardiologists
Pulmonologists
Rheumatologists
Critical Care Nurses
 

After completing this activity, participants will be better able to:
-Identify pathogenic mediators of PAH and understand how these pathways may affect choice of treatment
-Compare and contrast available treatments for PAH in terms of safety, efficacy, simplicity, manageability, adverse events, and drug  interactions
-Discuss recent clinical data for first-line therapy and long-term management of PAH in light of recent clinical findings
-Discuss when monotherapy should be used and when combination therapy should be considered for the treatment of PAH
-Develop and implement optimal treatment strategies for the individual patient with PAH
-Discuss future pathways for the treatment of PAH

Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Kentucky College of Medicine and HealthmattersCME. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the publication is provided solely by faculty who have been selected because of recognized expertise in their field.

All faculty members participating in continuing  medical education programs sponsored by the University of Kentucky College of Medicine are expected to disclose any real or perceived conflict of interest related to the content of the publication. Faculty disclosures are listed below.

Nursing 
The University of Kentucky College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

The Kentucky Board of Nursing (KBN) approves The University of Kentucky College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. This educational activity is offered for a maximum of 1.5 ANCC and 1 KBN contact hour for nurses who complete the entire program. Provider #: 3-0008-01-13-113. Please go online to www.cecentral.com/getcredit, enter the activity code XEN10111, and complete the posttest and credit request in order to receive CME/CE credit for the Faculty Feud: Current Concepts in Pathogenesis and Treatment of Pulmonary Arterial Hypertension monograph.

The University of Kentucky is an Equal Opportunity University.
 

Nicholas Hill, MD, has no real or apparent conflicts of interest to report, nor any financial relationships to disclose.

Mardi Gomberg-Maitland, MD, MSc
Contract Research Support: Actelion Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, ICOS, Pfizer, United Therapeutics Pharmaceuticals
Consultant: Biomarin, Gilead Sciences, Medtronic, Pfizer
Dr Gomberg-Maitland and her spouse are the co-inventors of a pending patent entitled “Compositions and Methods for Treating
Pulmonary Hypertension.” They do not receive royalties, licensing, income, or other payments resulting from this invention.

Ronald J. Oudiz, MD
Advisory Board: Actelion Pharmaceuticals, Bayer, Eli Lilly and Company, Gilead Sciences, LungRX, United Therapeutics Pharmaceuticals
Consultant: Actelion Pharmaceuticals, Bayer, Eli Lilly and Company, Gilead Sciences, LungRX, United Therapeutics Pharmaceuticals
Principle Investigator: Actelion Pharmaceuticals, Bayer, Eli Lilly and Company, Gilead Sciences, LungRX, United Therapeutics Pharmaceuticals

Myung H. Park, MD, FACC
Consultant: Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics
Advisory Board: Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics

Roham T. Zamanian, MD, FCCP
Advisory Board: United Therapeutics Pharmaceuticals
Contract Research Support: Actelion Pharmaceuticals
Consultant: Gilead Sciences




This activity is jointly sponsored by the University of Kentucky College of Medicine and HealthmattersCME.


This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
 
**Once the "Launch Activity" button is clicked, it may take a minute or more to download.